Accession Therapeutics Limited
Stephanie Smith Bewick has over 20 years of experience in the biotech and pharmaceutical industry, with expertise in business development and strategic planning. Throughout their career, they have held various senior roles in companies such as Accession Therapeutics Limited, Destiny Pharma plc, and Summit Therapeutics plc. As Chief Business Officer at Accession Therapeutics Limited, they are responsible for leading the business development efforts. Prior to that, they served as Chief Business Officer at Destiny Pharma plc, where they played a key role in business development activities. Stephanie also worked as Vice President, Business Development at Summit Therapeutics plc, where they led the out-licensing of product rights and conducted pipeline and acquisition valuations. Stephanie has also worked as an independent biotech business consultant and Senior Director at Apex Healthcare Consulting Ltd. Stephanie holds a strong background in areas such as product forecasting, commercial valuations, market access, and investment analysis. Stephanie's experience spans across various therapeutic areas, including orphan diseases, oncology, and neurology, and they have worked with different product types such as small molecules and biologicals. Overall, Stephanie brings a wealth of knowledge and expertise in business development and strategic planning to their roles in the biotech and pharmaceutical industry.
Stephanie Smith Bewick completed their education in the field of Neuroscience. Stephanie started their educational journey in 1985 at St Andrew's College, Dublin. However, no specific degree or field of study is mentioned for this period. Later, they pursued a Bachelor of Science (BSc Hons) in Neuroscience from The University of Edinburgh, where they studied from 1991 to 1995. After completing their undergraduate degree, Stephanie went on to obtain a Doctor of Philosophy (PhD) in Neuroscience from the University of Bristol between 1995 and 1999.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.